Back to Newsroom

Auris Medical and King’s College London Extend Tinnitus Collaboration

– Selection of lead compound for AM-102 program planned for 2017

ZUG, Switzerland, Feb. 22, 2017 (GLOBE NEWSWIRE) — Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the extension of its collaboration with King’s College London. The collaboration is focused on the discovery of small molecule compounds for a second generation tinnitus treatment.

Click here to read the full release